Why the study?
Does adjuvant therapy improve survival in patients with extraskeletal osteosarcoma compared to stage III extremity sarcomas?
Does adjuvant therapy improve survival in patients with extraskeletal osteosarcoma compared to stage III extremity sarcomas?
Extraskeletal osteosarcoma has a 5-year survival of 50%, comparable to stage III extremity sarcomas, and should be treated following established soft-tissue sarcoma guidelines.
No takes yet. Share an insight, caveat, or question.
Comparable survival supports guideline-directed soft-tissue sarcoma management; leaves open adjuvant therapy benefit in this rare cohort.
McCarter et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: